✦ LIBER ✦

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

✍ Scribed by Larkin, James; Del Vecchio, Michele; Ascierto, Paolo A; Krajsova, Ivana; Schachter, Jacob; Neyns, Bart; Espinosa, Enrique; Garbe, Claus; Sileni, Vanna Chiarion; Gogas, Helen; Miller, Wilson H; Mandalà, Mario; Hospers, Geke A P; Arance, Ana; Queirolo, Paola; Hauschild, Axel; Brown, Michael P; Mitchell, Lada; Veronese, Luisa; Blank, Christian U

Book ID: 122300534
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 297 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70051-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vemurafenib in patients with BRAFV600 mu

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

✍ Dummer, Reinhard; Goldinger, Simone M.; Turtschi, Christian P.; Eggmann, Nina B. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 702 KB

Combination of vemurafenib and cobimetin

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

✍ Ribas, Antoni; Gonzalez, Rene; Pavlick, Anna; Hamid, Omid; Gajewski, Thomas F; D 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 466 KB

A phase I, randomized, open-label study

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients withBRAFV600Emutation-positive metastatic melanoma

✍ Grippo, J. F.; Zhang, W.; Heinzmann, D.; Yang, K. H.; Wong, J.; Joe, A. K.; Muns 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 442 KB

Dabrafenib in patients with Val600Glu or

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

✍ Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascie 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 259 KB

Safety and efficacy of sunitinib in pati

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

✍ Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 178 KB

Efficacy and safety of donepezil over 3

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease

✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##